Core Viewpoint - The company has signed a maximum guarantee contract with China Everbright Bank to provide a joint liability guarantee for its subsidiary, Zhengzhou Deep Blue Marine Pharmaceutical Technology Co., Ltd., with a maximum principal amount of RMB 3 million [1][3]. Group 1: Guarantee Details - The guarantee is intended to support the operational development of the subsidiary, Deep Blue Marine, and is part of a comprehensive credit agreement valid from January 9, 2026, to January 8, 2027 [1][3]. - The company has approved a total guarantee limit of up to RMB 43 million for its subsidiaries for the year 2025, which can be adjusted internally based on actual operational needs [1][2]. - The guarantee covers all debts, including principal, interest, penalties, and other related costs incurred under the comprehensive credit agreement [3]. Group 2: Internal Decision-Making Process - The board of directors approved the guarantee proposal during meetings held on April 7, 2025, and April 29, 2025, ensuring compliance with internal approval procedures [1][4]. - The board believes that the guarantee will enhance financing efficiency and reduce costs, aligning with the company's operational needs and overall development strategy [4]. Group 3: Financial Position and Risk Assessment - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to RMB 297.03 million, representing 18.86% of the latest audited net assets [5]. - The company has not provided guarantees for controlling shareholders or related parties and has not experienced any overdue guarantees [5].
河南太龙药业股份有限公司 关于为下属控股子公司融资提供担保的进展公告